REG-IQE plc : Placing of new shares raising £95 million <Origin Href="QuoteRef">IQE.L</Origin>

IqeAnnouncement

10/11/2017 07:00

For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20171110:nGNE6CwP9l


THIS ANNOUNCEMENT, INCLUDING THE INFORMATION CONTAINED HEREIN, IS NOT FOR
RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN,
THE REPUBLIC OF SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE,
PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT IS NOT AN
OFFER OF SECURITIES FOR SALE OR SOLICITATION OF AN OFFER TO BUY THE SECURITIES
DISCUSSED HEREIN IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR IN ANY
JURISDICTION IN WHICH SUCH OFFER OR SOLICITATION IS UNLAWFUL.

IQE plc

10 November 2017

Placing of new shares raising £95 million

IQE plc (AIM: IQE, "IQE" or the "Company"), a leading global supplier of
advanced wafer products and wafer services to the semiconductor industry,
today announces that further to the announcement made on 9 November 2017
regarding the proposed placing of ordinary shares, it has successfully placed
67,941,581 new ordinary shares of 1 pence each in the Company (the "Placing
Shares"), at a price of 140 pence per share, raising gross proceeds of
approximately £95 million (the "Placing").

The Placing Shares represent approximately 9.9% of IQE's existing outstanding
issued share capital. Application for admission of the Placing Shares to
trading on AIM will be made in due course and the Placing Shares are expected
to commence trading on 16 November 2017 ("Admission") (at which time the
Placing will become unconditional). The Placing is expected to settle on 16
November 2017, subject to Admission.

The Company's enlarged issued ordinary share capital immediately following the
issue of the Placing Shares will be 754,756,394 voting ordinary shares. The
aforementioned figure of 754,756,394 voting ordinary shares may be used by
shareholders as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a change of
interest in, the share capital of the Company under the Disclosure Guidance
and Transparency Rules.

Following completion of the transaction, the Company has agreed to a lock-up
of 90 days.

Canaccord Genuity Limited ("Canaccord Genuity"), Stifel Nicolaus Europe
Limited ("Stifel") and Peel Hunt LLP ("Peel Hunt") acted as joint bookrunners
in relation to the Placing (the "Bookrunners").

For further information, please contact:

 IQE plc Drew Nelson Phil Rasmussen Chris Meadows                                         Tel: +44 (0)29 2083 9400   
 Canaccord Genuity (Nomad, Joint Bookrunner) Simon Bridges Antony Isaacs Richard Andrews  Tel: +44 (0)20 7523 8000   
 Stifel (Joint Bookrunner) Fred Walsh Neil Shah Ben Maddison                              Tel: +44 (0)20 7710 7600   
 Peel Hunt (Joint Bookrunner)                                                             Tel: +44 (0) 20 7418 8900  
  Edward Knight Nick Prowting                                                                                        

About IQE:

IQE is a leading global supplier of advanced semiconductor wafers with
products that cover a diverse range of applications. The Group's outsourced
foundry services provides a 'one stop shop' for the wafer needs of the world's
leading semiconductor manufacturers.

IQE uses advanced epitaxial growth technology platforms to manufacture and
supply advanced semiconductor 'epi-wafers' to the major chip manufacturing
companies, who then use these wafers to make the chips which form the key
components of virtually all high technology systems.

IQE's products are found in many consumer, communication, computing, mobility
and industrial applications. IQE's epi-wafers enable a wide range of
wireless/RF, photonics, infrared, power, solar, advanced electronics and
sensor technologies.

IQE operates multiple manufacturing and R&D facilities across Europe, Asia and
the USA.

This announcement is restricted, and is not for publication, release or
distribution, directly or indirectly, in whole or in part, in or into the
United States, Canada, Australia, New Zealand, Japan, the Republic of Ireland
or the Republic Of South Africa or any other jurisdiction in which such
publication or distribution would be unlawful.

This announcement does not constitute an offer to sell, or a solicitation of
an offer to buy, securities in the United States. The securities mentioned
herein have not been and will not be registered under the US Securities Act of
1933 ("Securities Act"), as amended or under any securities laws of any state
or other jurisdiction of the United States and may not be offered, sold,
resold, transferred or delivered, directly or indirectly, in or into the
United States, except to "qualified institutional buyers" ("QIBS", as the term
is defined in rule 144a under the Securities Act), in reliance on an exemption
from the registration requirements of the securities act, or in a transaction
not subject to the registration requirements of the securities act and, in
each case, in compliance with the securities laws of any state or other
jurisdiction of the United States. There will be no public offer of the
securities within the meaning of section 4(a)2 of the Securities Act made in
the United States.

The securities mentioned herein will have not been approved or disapproved by
the SEC, any state securities commission or any other regulatory authority in
the United States, nor have any of the foregoing authorities passed upon or
endorsed the merits of the placing or the accuracy or adequacy of the contents
of this announcement. Any representation to the contrary is a criminal offence
in the United States.

This announcement contains inside information as defined in Article 7 of the
Market Abuse Regulation No. 596/2014.  Upon the publication of this
announcement, this inside information is now considered to be in the public
domain.

Canaccord Genuity, Stifel and Peel Hunt, which are authorised and regulated in
the United Kingdom by the FCA is acting for the Company and no one else in
relation to the Placing and Admission and they will not be responsible to
anyone other than the Company for providing the protections afforded to
customers of Canaccord Genuity, Stifel and Peel Hunt or for providing advice
in relation to any matter contained in this document or any matter or
arrangement referred to in it. No representation or warranty, express or
implied, is or will be made as to, or in relation to, and no responsibility or
liability is or will be accepted by Canaccord Genuity, Stifel and Peel Hunt,
or by any of their affiliates or agents, as to or in relation to, the accuracy
or completeness of this announcement or any other written or oral information
made available to or publicly available to any interested party or its
advisers, and any liability therefore is expressly disclaimed.

Certain statements in this announcement may be forward-looking. Although the
Company believes that the expectations reflected in these forward looking
statements are reasonable, it can give no assurance or guarantee that these
expectations will prove to have been correct. Because these statements involve
risks and uncertainties, actual results may differ materially from those
expressed or implied by these forward looking statements.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of
Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for
the content, accuracy and originality of the information contained therein.
Source: IQE plc via Globenewswire